Telo Genomics Appoints John Farlinger to its Board of Directors
Toronto, Ontario – April 4, 2025 – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo Genomics”), a pioneering biotech company specializing in the development of diagnostic and prognostic tests for human diseases through the analysis of chromosomal telomeres, is thrilled to announce the addition of a new member to its esteemed Board of Directors. Effective immediately, Mr. John Farlinger will assume this role and will also take on the responsibility of Chairing the Company’s audit committee.
Background of John Farlinger
John Farlinger brings a wealth of experience in finance, accounting, and governance to Telo Genomics. He has spent the last 30 years working in various senior financial positions in both public and private companies. Over the past 15 years, he has dedicated his time to serving as a financial consultant and advisor to several biotech and technology firms. His expertise in financial reporting, risk management, and corporate governance will significantly contribute to the strategic growth of Telo Genomics.
Impact on Telo Genomics
The appointment of Mr. Farlinger is a significant step forward for Telo Genomics as it continues to expand its reach and impact in the diagnostics industry. His extensive financial background and experience in corporate governance will provide valuable insight and leadership as the company navigates its growth trajectory. John’s expertise will be instrumental in ensuring the Company’s financial reporting is accurate, transparent, and compliant with regulatory requirements.
Personal and Global Implications
For individuals, the addition of Mr. Farlinger to Telo Genomics’ Board of Directors signifies a commitment to maintaining the highest standards of financial reporting and corporate governance. This dedication will instill confidence in current and future investors, ensuring that their investments are being managed responsibly and transparently. Moreover, the advancements in diagnostic testing made possible by Telo Genomics have the potential to revolutionize healthcare, enabling earlier detection and more effective treatments for numerous diseases.
Global Impact
On a global scale, the advancements in diagnostic testing made possible by Telo Genomics have the potential to revolutionize healthcare. By enabling earlier detection and more effective treatments for numerous diseases, Telo Genomics’ innovative solutions can significantly improve health outcomes and reduce healthcare costs. The appointment of Mr. Farlinger to the Board of Directors further reinforces the company’s commitment to maintaining the highest standards of financial reporting and corporate governance, ensuring a sustainable and responsible growth path for the future.
Conclusion
Telo Genomics’ appointment of John Farlinger to its Board of Directors and as Chair of the audit committee is an essential step towards maintaining the company’s financial integrity and ensuring its continued growth. With his extensive background in finance, accounting, and corporate governance, Mr. Farlinger will provide invaluable insight and leadership as Telo Genomics continues to expand its reach and impact in the diagnostics industry. This commitment to financial reporting and corporate governance, combined with the potential of its innovative diagnostic testing solutions, positions Telo Genomics to make a significant impact on both individual health and global healthcare costs.
- Telo Genomics appoints John Farlinger to Board of Directors and audit committee
- Farlinger brings extensive financial and corporate governance experience
- Impact on Telo Genomics: financial reporting, risk management, and strategic growth
- Personal and Global Implications: confidence in investments, healthcare advancements
- Global Impact: potential to revolutionize healthcare, reduce costs
